Makoto Maemondo

Prof. Dr. Makoto Maemondo

Division of Pulmonary Medicine, Department of Internal Medicine, Iwate Medical University School of Medicine Yahaba, Iwate, Japan
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in The Lancet Oncology
Verified
Journal Article
Closed access
HSHaruhiro Saito
Haruhiro Saito
TFTatsuro Fukuhara
Tatsuro Fukuhara
NFNaoki Furuya
Naoki Furuya
KWKana Watanabe
Kana Watanabe
SSShunichi Sugawara
Shunichi Sugawara
MMMakoto Maemondo
Makoto Maemondo

1 January 2022 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
YKYosuke Kawashima
Yosuke Kawashima
TFTatsuro Fukuhara
Tatsuro Fukuhara
HSHaruhiro Saito
Haruhiro Saito
NFNaoki Furuya
Naoki Furuya
KWKana Watanabe
Kana Watanabe
MMMakoto Maemondo
Makoto Maemondo

1 July 2020 in EBioMedicine
Verified
Journal Article
Open access
TFTatsuro Fukuhara
Tatsuro Fukuhara
HSHaruhiro Saito
Haruhiro Saito
NFNaoki Furuya
Naoki Furuya
KWKana Watanabe
Kana Watanabe
SSShunichi Sugawara
Shunichi Sugawara
MMMakoto Maemondo
Makoto Maemondo
The NEJ026 Phase 3 study demonstrated that erlotinib and bevacizumab (BE)-treated NSCLC patients with EGFR mutations had significantly better progression-free survival (PFS) than those treated with erlotinib alone (E). This study included a prospective analysis of the relationship between the mutational status of EGFR in plasma circulating tumor DNA (ctDNA) and the efficacy of TKI monotherapy or combination therapy. We describe these results herein. Plasma samples were collected from patients enrolled in NEJ026 at the start of treatment (P0), 6 weeks after the start of treatment (P1), and upon confirmation of progressive disease (P2). Plasma ctDNA was analyzed using a modified PNA-LNA PCR clamp method. PFS and OS according to EGFR status at the time of plasma collection were evaluated. Plasma activating EGFR mutation (aEGFR) at P0 was detected in 68% of cases; patients without plasma aEGFR had longer PFS. The frequency of T790M mutation at P2 was similar in both arms: 8 (19.0%) in BE and 11 (20.8%) in E. Based on the aEGFR profiles, PFS was evaluated among three groups: type A [P0(-), P1(-)], type B [P0(+), P1(-)], and type C [P0(+), P1(+)]. This revealed that BE was more efficacious than E, and that BE was associated with improved PFS in all types. Pre-treatment plasma aEGFR status have a potential of early predictor of response of TKI efficacy. Monitoring plasma aEGFR mutation will contribute to selection and continuation of treatment with BE or E. Chugai Pharmaceutical.

13 July 2016 in Canadian Respiratory Journal
Verified
Journal Article
Open access
PDF file
KWKana Watanabe
Kana Watanabe
TFTatsuro Fukuhara
Tatsuro Fukuhara
YTYoko Tsukita
Yoko Tsukita
MMMami Morita
Mami Morita
ASAya Suzuki
Aya Suzuki
MMMakoto Maemondo
Makoto Maemondo
Introduction. Rebiopsies have become more crucial in non-small cell lung cancer (NSCLC). Instead of invasive biopsies, development of collecting biological data of the tumor from blood samples is expected. We conducted a prospective study to assess the feasibility of detection of epidermal growth factor receptor (EGFR) mutation in plasma samples.Method. NSCLC patients harboring EGFR activating mutations, who were going to receive EGFR-tyrosine kinase inhibitors (TKIs) as first-line treatment, were enrolled in this study. Plasma EGFR activating mutations and the T790M resistance mutation were analyzed by an improved PNA-LNA PCR clamp method, characterized by a 10-fold or more sensitivity compared with the original methods.Result. Six patients with wild-type EGFR and 24 patients with EGFR mutations were enrolled in this study. Pretreatment plasma samples achieved sensitivity of 79%. The 6 patients with wild-type EGFR were all negative for plasma EGFR mutations. At the time of disease progression, plasma T790M mutation was detected in 8 of 16 cases. Absence of T790M before and during TKI treatment and disappearance of activating mutations during TKI treatment were considered as predictors of EGFR-TKIs efficacy.Conclusion. We were able to detect EGFR mutations in plasma samples by using an improved PNA-LNA PCR clamp method.

30 December 2019 in BMJ Case Reports
Verified
Journal Article
Open access
PDF file
HSHirotaka Saikawa
Hirotaka Saikawa
HNHiromi Nagashima
Hiromi Nagashima
TMTetsuya Maeda
Tetsuya Maeda
MMMakoto Maemondo
Makoto Maemondo
A 71-year-old male patient with adenocarcinoma of the lung and contralateral lung metastasis under administration of pembrolizumab had symptoms of cerebellar ataxia. We suspected that the symptoms were immune-related adverse events (irAE), but the patient was subsequently diagnosed as cerebellitis due to Epstein-Barr virus (EBV) infection. After steroid pulse therapy, the symptoms of cerebellar ataxia improved immediately. Immune checkpoint inhibitors (ICI) can induce neurological adverse events and cause acute cerebellar ataxia. Initially, irAEs were suspected in this case. His clinical data suggested that reactivation of the virus had occurred because the ICI affected his immune system. This is the first report of a case of acute cerebellar ataxia due to EBV under administration of an ICI.

13 December 2021 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
TITakashi Ito
Takashi Ito
HNHiromi Nagashima
Hiromi Nagashima
MAMasachika Akiyama
Masachika Akiyama
YUYu Utsumi
Yu Utsumi
HSHideomi Sato
Hideomi Sato
MMMakoto Maemondo
Makoto Maemondo
Background: Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) have become the gold standard for EGFR‐mutated non‐small cell lung cancer (NSCLC) treatment. Immune checkpoint inhibitors (ICIs) have been developed for the treatment of several malignancies, including lung cancer. However, it is known that ICIs have poorer efficacy in EGFR‐mutated NSCLC.Methods: We collected data for patients with EGFR‐mutated NSCLC receiving monotherapy with ICIs after EGFR‐TKIs between December 2015 and March 2020 in three institutions, and retrospectively analyzed the association between patient characteristics and efficacy of ICIs.Results: A total of 25 patients were included in this study. We defined responders as patients undergoing 90 days or longer of ICI treatment. Comparing characteristics between responders and non‐responders, more tumors with L858R EGFR mutation were observed in responders than in non‐responders (L858R: 66.7% and 25.0%, respectively, p < 0.05). There was no difference in incidence of T790M resistance mutation before ICI treatment. The PD‐L1 positive rate was slightly higher in responders but not statistically significant (22.2% and 12.5%, respectively). Median duration of EGFR‐TKI pretreatment was shorter in ICI responders compared with nonresponders (13.3 and 19.9 months, respectively). The survival of patients with L858R tumors was significantly longer than that of patients with exon 19 deletion (HR: 0.35, 95% CI: 0.13–0.93, p = 0.026).Conclusions: ICI treatment tends to have better efficacy in patients with L858R‐mutated tumors. This study suggests that patients with L858R‐mutated NSCLC are candidates for ICI treatment after EGFR‐TKI treatment.